Calder’s vaccine has +75% Efficacy target, including in the elderly


$3.4B Global Market Opportunity
  • Pandemic influenza poses a real and present threat of outbreaks with high fatality rates. Each year, seasonal flu causes:
    • 9M-45M illnesses – causing a substantial loss working days and a major burden on society
    • 140K-800k hospitalizations - loss of independence, high burden on community and healthcare system
    • 12K-80k deaths, primarily in the elderly
  • Seasonal flu vaccines are poorly effective ranging from 10% to 60% efficacy, depending on seasonal match; pandemic strains cannot be predicted.
  • Calder’s universal flu vaccine will achieve pandemic preparedness and simultaneously reduce seasonal disease burden, by inducing antibodies to parts of a viral surface protein common to all strains of influenza
    • Variable ”Head” domain of the HA protein is removed (“Headless”); focuses antibody responses on the highly conserved “Stalk”
    • Headless has the greatest potential for universal protection
Flu virus infecting a cell. Colored transmission electron micrograph of stages of a respiratory tract cell infection of an influenza virus. The virus appears rounded in shape, with a core of ribonucleic acid (RNA). It has a spiked outer coat which allows the virus to attach to host cells. Host cell cytoplasm appears granular. At top frames (3 images) the virus attaches to the cell, causing the cell membrane to fold around the virus. At lower frames (3 images) the virus penetrates the cell, infecting it, and will then cause more influenza viruses to be produced by the infected cell. Magnification: x50,000 (for each inset) at 5x7cm size. x180,000 for each 3x3 inch size inset at 10x8"


Sources: Global Seasonal Influenza Vaccines Drug Market Analysis & Forecast Report, Dec 2019 (ID:4861087), Calder Research; https://www.cdc.gov: Disease Burden of Influenza, 2 https://www.statnews.com/2018/09/26/cdc-us-flu-deaths-winter/ webmd.com: How Effective Is The Flu Vaccine (Sep 2020)